AIM: To deduce strategic guidelines of gastric mucosa associated lymphoid tissue lymphoma (MALTOMA) by evaluating the long-term outcome of patients in respect to various treatment modalities. METHODS: A total of 55 patients with MALTOMA from May 1992 to August 2002 were retrospectively reviewed. RESULTS: Complete remission was obtained in 24 (82.8%) of 29 patients treated with anti Helicobacter pylori (H pylori) regimen only. The duration to reach complete remission was 12 months (85 percentile, 2-33 months). Five patients showed complete remission with radiation therapy (26-86 months). Two of them were H pylori treatment failure cases. CONCLUSION: H pylori eradication is an effective primary treatment option for low grade MALTOMA and radiation therapy could be considered in patients with no evidence of H pylori infection or who do not respond to H pylori eradication therapy 12 months after successful eradication.
AIM: To deduce strategic guidelines of gastric mucosa associated lymphoid tissue lymphoma (MALTOMA) by evaluating the long-term outcome of patients in respect to various treatment modalities. METHODS: A total of 55 patients with MALTOMA from May 1992 to August 2002 were retrospectively reviewed. RESULTS: Complete remission was obtained in 24 (82.8%) of 29 patients treated with anti Helicobacter pylori (H pylori) regimen only. The duration to reach complete remission was 12 months (85 percentile, 2-33 months). Five patients showed complete remission with radiation therapy (26-86 months). Two of them were H pylori treatment failure cases. CONCLUSION:H pylori eradication is an effective primary treatment option for low grade MALTOMA and radiation therapy could be considered in patients with no evidence of H pylori infection or who do not respond to H pylori eradication therapy 12 months after successful eradication.
Authors: T Hiyama; K Haruma; Y Kitadai; H Masuda; M Miyamoto; M Ito; T Kamada; S Tanaka; N Uemura; M Yoshihara; K Sumii; F Shimamoto; K Chayama Journal: J Gastroenterol Hepatol Date: 2001-07 Impact factor: 4.029
Authors: M Sackmann; A Morgner; B Rudolph; A Neubauer; C Thiede; H Schulz; W Kraemer; G Boersch; P Rohde; E Seifert; M Stolte; E Bayerdoerffer Journal: Gastroenterology Date: 1997-10 Impact factor: 22.682
Authors: C Montalban; A Santon; D Boixeda; C Redondo; I Alvarez; J L Calleja; C M de Argila; C Bellas Journal: Haematologica Date: 2001-06 Impact factor: 9.941
Authors: A Savio; G Franzin; A C Wotherspoon; G Zamboni; R Negrini; F Buffoli; T C Diss; L Pan; P G Isaacson Journal: Blood Date: 1996-02-15 Impact factor: 22.113
Authors: Carlo A Fallone; Alan N Barkun; Andrew Szilagyi; Karl M Herba; Maida Sewitch; Myriam Martel; Stefanie S Fallone Journal: Can J Gastroenterol Date: 2013-07 Impact factor: 3.522
Authors: Sang-Won Kim; Do Hoon Lim; Yong Chan Ahn; Won Seog Kim; Seok Jin Kim; Young Hyeh Ko; Kyoung-Mee Kim Journal: World J Gastroenterol Date: 2013-09-28 Impact factor: 5.742
Authors: Khalid O Alfarouk; Adil H H Bashir; Ahmed N Aljarbou; AbdelRahman M Ramadan; Abdel Khalig Muddathir; Sari T S AlHoufie; Abdelhamid Hifny; Gamal O Elhassan; Muntaser E Ibrahim; Saad S Alqahtani; Shakir D AlSharari; Claudiu T Supuran; Cyril Rauch; Rosa Angela Cardone; Stephan J Reshkin; Stefano Fais; Salvador Harguindey Journal: Front Oncol Date: 2019-02-22 Impact factor: 6.244